Related references
Note: Only part of the references are listed.MET inhibitors in cancer: pitfalls and challenges
Helena Oliveres et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2
Baohui Qi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy-)6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment
Baohui Qi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
Omidreza Firuzi et al.
CANCERS (2019)
Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors
Leonardo Pisani et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Optimization techniques for novel c-Met kinase inhibitors
Zhi-Gang Sun et al.
EXPERT OPINION ON DRUG DISCOVERY (2019)
Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities
Baohui Qi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Recent advances in the discovery of small molecule c-Met Kinase inhibitors
Palak K. Parikh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
Vicki L. Keedy et al.
INVESTIGATIONAL NEW DRUGS (2018)
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
Istvan Szabadkai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
Oshin Miranda et al.
CANCERS (2018)
RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells
Binbin Yin et al.
ONCOLOGY REPORTS (2017)
c-Met targeting in advanced gastric cancer: An open challenge
Luigi Marano et al.
CANCER LETTERS (2015)
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
J. Jean Cui
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Ron receptor tyrosine kinase signaling as a therapeutic target
Nancy M. Benight et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
Jocelyn Logan-Collins et al.
CANCER RESEARCH (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma
Jing Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Targeting the c-MET signaling pathway for cancer therapy
Xiangdong Liu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells
Carla Boccaccio et al.
NATURE REVIEWS CANCER (2006)
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen et al.
CANCER LETTERS (2005)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase
MH Wang et al.
CARCINOGENESIS (2003)
Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Alla Danilkovitch-Miagkova
CURRENT CANCER DRUG TARGETS (2003)
Share Paper
